Losartan in Prevention of Radiation-Induced Heart Failure

Launched by MASSACHUSETTS GENERAL HOSPITAL · Nov 1, 2022

Keywords

ClinConnect Summary

This clinical trial is studying whether a medication called losartan can help prevent heart problems caused by radiation therapy in women with non-metastatic breast cancer. Radiation therapy is a common treatment for this type of cancer, but it can sometimes lead to heart issues later on. The trial aims to see if taking losartan while receiving radiation therapy can lower the chance of developing heart failure.

To participate in this study, women aged 18 and older who have left-sided breast cancer and are scheduled to receive radiation therapy may be eligible. Participants should be able to understand the study and give their consent, and they must not be pregnant or breastfeeding. Throughout the trial, participants will receive standard radiation treatment alongside losartan. It’s important to note that this trial is currently recruiting participants, and anyone interested should discuss it with their healthcare provider to see if they qualify.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • -\>18 years of age
• • Non-metastatic Breast Cancer patients who are scheduled to receive conventional left breast/chest wall RT inclusive of treatment to the internal mammary lymph nodes (IMNs)
• • Prior chemotherapy is permitted
• • Patients must have Left-sided Breast Cancer
• • Ability to understand and the willingness to sign a written informed consent document
• • No contraindication to MRI
• Exclusion Criteria:
• • Person who is pregnant or breastfeeding.
• • Patient unable to swallow oral medication.
• • Patients receiving any other investigational agent will not be excluded from study eligibility, unless the patient is already enrolled in an interventional study evaluating cardiac toxicity
• • Patients already receiving ACE/ARBs.
• • Patients with a history of allergic reactions to Losartan biosimilars.